Erva-mate influence on iron absorption from the diet in people with hereditary iron overload
Not Applicable
Recruiting
- Conditions
- disorders of iron metabolismhemochromatosisE83.1C16.320.565.618.337
- Registration Number
- RBR-5nrrwc
- Lead Sponsor
- niversidade Federal de Santa Catarina
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
hereditary hemochromatosis; live in Florianópolis, State of Santa Catarina Brazil; a minimum age limit of 18 years; maintenance treatment; homozygous for the C282Y mutation in HFE; absence of anemia and a minimum interval of one month from the last phlebotomy.
Exclusion Criteria
Use of chelating agents 24 hours prior to the start of the study; presence of acute or chronic infections; cancer; diagnosis for secondary hemochromatosis and in women in the menstrual phase of the menstrual cycle.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does erva-mate use to modulate iron absorption in hereditary hemochromatosis?
How does erva-mate compare to phlebotomy in managing iron overload in HFE-related hemochromatosis patients?
Are there specific biomarkers that correlate with erva-mate's efficacy in reducing iron absorption?
What are the potential adverse effects of erva-mate consumption in patients with iron metabolism disorders?
What other natural compounds or drugs synergize with erva-mate to inhibit iron overload progression?